Literature DB >> 29449338

Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015.

Zengwu Wang1, Zuo Chen2, Linfeng Zhang2, Xin Wang2, Guang Hao3, Zugui Zhang4, Lan Shao2, Ye Tian2, Ying Dong2, Congyi Zheng2, Jiali Wang2, Manlu Zhu2, William S Weintraub5, Runlin Gao6.   

Abstract

BACKGROUND: Although the prevalence of hypertension (HTN) continues to increase in developing countries, including China, recent data are lacking. A nationwide survey was conducted from October 2012 to December 2015 to assess the prevalence of HTN in China.
METHODS: A stratified multistage random sampling method was used to obtain a nationally representative sample of 451 755 residents ≥18 years of age from 31 provinces in mainland China from October 2012 to December 2015. Blood pressure (BP) was measured after resting for 5 minutes by trained staff using a validated oscillometric BP monitor. HTN was defined as systolic BP (SBP) ≥140 mm Hg/or diastolic BP (DBP) ≥90 mm Hg or use of antihypertensive medication within 2 weeks. Pre-HTN was defined as SBP 120 to 139 mm Hg and DBP 80 to 89 mm Hg without antihypertensive medication. HTN control was defined as SBP <140 mm Hg and DBP<90 mm Hg. In addition, the prevalence of HTN (SBP ≥130 or DBP ≥80 mm Hg) and control rate (SBP <130 and DBP <80 mm Hg) of HTN were also estimated according to the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline.
RESULTS: Overall, 23.2% (≈244.5 million) of the Chinese adult population ≥18 years of age had HTN, and another 41.3% (≈435.3 million) had pre-HTN according to the Chinese guideline. There were no significant differences of HTN prevalence between urban and rural residents (23.4% versus 23.1%, P=0.819). Among individuals with HTN, 46.9% were aware of their condition, 40.7% were taking prescribed antihypertensive medications, and 15.3% had controlled HTN. Calcium channel blockers were the most commonly used antihypertensive medication (46.5%) as monotherapy, and 31.7% of treated hypertensive patients used ≥2 medications. The prevalence of HTN based on the 2017 American College of Cardiology/American Heart Association guideline was twice as high as that based on 2010 Chinese guideline (46.4%), whereas the control rate fell to 3.0%.
CONCLUSIONS: In China, there is a high prevalence of HTN and pre-HTN, and awareness, treatment, and control of HTN were low. Management of medical therapy for HTN needs to improve.
© 2018 American Heart Association, Inc.

Entities:  

Keywords:  China; antihypertensive medication; awareness; control; hypertension; prevalence

Mesh:

Substances:

Year:  2018        PMID: 29449338     DOI: 10.1161/CIRCULATIONAHA.117.032380

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  407 in total

Review 1.  Unique approaches to hypertension control in China.

Authors:  Ji-Guang Wang
Journal:  Ann Transl Med       Date:  2018-08

Review 2.  Global Updates on Cardiovascular Disease Mortality Trends and Attribution of Traditional Risk Factors.

Authors:  Ram Jagannathan; Shivani A Patel; Mohammed K Ali; K M Venkat Narayan
Journal:  Curr Diab Rep       Date:  2019-06-20       Impact factor: 4.810

Review 3.  Prevalence of high blood pressure under 2017 ACC/AHA guidelines: a systematic review and meta-analysis.

Authors:  Peisheng Xiong; Zhixi Liu; Meijuan Xiong; Feng Xie
Journal:  J Hum Hypertens       Date:  2020-12-08       Impact factor: 3.012

4.  Association between animal source foods consumption and risk of hypertension: a cohort study.

Authors:  Jie Liang; Jun-Kang Zhao; Ju-Ping Wang; Tong Wang
Journal:  Eur J Nutr       Date:  2020-11-05       Impact factor: 5.614

Review 5.  Gender Differences in Hypertension.

Authors:  Juan-Juan Song; Zheng Ma; Juan Wang; Lin-Xi Chen; Jiu-Chang Zhong
Journal:  J Cardiovasc Transl Res       Date:  2019-05-01       Impact factor: 4.132

6.  Trends and Status of the Prevalence of Elevated Blood Pressure in Children and Adolescents in China: a Systematic Review and Meta-analysis.

Authors:  Lulin Wang; Lulu Song; Bingqing Liu; Lina Zhang; Mingyang Wu; Zhongqiang Cao; Youjie Wang
Journal:  Curr Hypertens Rep       Date:  2019-10-10       Impact factor: 5.369

7.  Health-related quality of life among rural men and women with hypertension: assessment by the EQ-5D-5L in Jiangsu, China.

Authors:  Zhuoru Liang; Tiantian Zhang; Tengfei Lin; Lishun Liu; Binyan Wang; Alex Z Fu; Xiaobin Wang; Xiping Xu; Nan Luo; Jie Jiang
Journal:  Qual Life Res       Date:  2019-03-04       Impact factor: 4.147

8.  Berberine-Promoted CXCR4 Expression Accelerates Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Persons with Prehypertension.

Authors:  Yi-Jia Shao; Jun Tao; Bing-Bo Yu; Dan Meng; Xu-Long Yang; Jia-Pan Sun; Yan-Xia Qiu; Xiao-Yu Zhang
Journal:  Chin J Integr Med       Date:  2018-10-19       Impact factor: 1.978

9.  Association of a Province-Wide Intervention With Salt Intake and Hypertension in Shandong Province, China, 2011-2016.

Authors:  Aiqiang Xu; Jixiang Ma; Xiaolei Guo; Linhong Wang; Jing Wu; Jiyu Zhang; Yamin Bai; Jianwei Xu; Zilong Lu; Zhongji Xu; Xiaochang Zhang; Gangqiang Ding; Yuling Hong; Fengjun Du; Yangfeng Wu; Liuxia Yan; Junli Tang; Xiaoning Cai; Jing Dong; Chunxiao Xu; Jie Ren; Xi Chen; Congcong Gao; Bingyin Zhang; Quanhe Yang; Ronald Moolenaar; Ying Cai; Sandra L Jackson; Gaoqiang Xie; Shicheng Yu; Jing Cui; Zengwu Wang; Liyun Zhao; Lahong Ju; Danyang Shen; Shumei Yun; Xiaofeng Liang; Zhenqiang Bi; Yu Wang
Journal:  JAMA Intern Med       Date:  2020-06-01       Impact factor: 21.873

10.  Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.

Authors:  Yanzhi Li; Lu Tian; Han Zheng; Chongqi Jia
Journal:  Ann Med       Date:  2020-07-22       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.